Durect (Durect) ROCE %

: -18.23% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Durect's annualized ROCE % for the quarter that ended in Dec. 2023 was -18.23%.

Durect ROCE % Historical Data

The historical data trend for Durect's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Durect Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-41.21

-21.19

-46.46

-60.97

-112.17

Durect Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %																-96.69	-212.68	-355.28	-73.48	-18.23

Durect ROCE % Calculation

Durect's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-24.832	/	( ( (60.1 - 34.004)	+	(45.189 - 27.011) )	/ 2 )
	=	-24.832	/	( (26.096	+	18.178)	/ 2 )
	=	-24.832	/	22.137
	=	-112.17 %

Durect's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-3.296	/	( ( (54.728 - 36.752)	+	(45.189 - 27.011) )	/ 2 )
	=	-3.296	/	( ( 17.976	+	18.178 )	/ 2 )
	=	-3.296	/	18.077
	=	-18.23 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Durect (NAS:DRRX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Durect ROCE % Related Terms

Thank you for viewing the detailed overview of Durect's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Durect (Durect) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Durect Corp (NAS:DRRX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

DC8A:Germany

Address

10260 Bubb Road, Cupertino, CA, USA, 95014

Website

https://www.durect.com

Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .

Executives

Judith J. Robertson	director	10260 BUBB ROAD, CUPERTINO CA 95014
Gail J Maderis	director	364 LOMBARD ST., SAN FRANCISCO CA 94133
Timothy M. Papp	officer: Chief Financial Officer	C/O DURECT CORPORATION, 10260 BUBB ROAD, CUPERTINO CA 95014
Gail M Farfel	director	142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Mohammad Azab	director	C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Peter S Garcia	director	ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Simon X Benito	director	967 LAWRENCE AVE, WESTFIELD NJ 07090
Norman Sussman	officer: Chief Medical Officer	C/O DURECT CORP., 10260 BUBB ROAD, CUPERTINO CA 95014
Bleichroeder Lp	10 percent owner	1345 AVENUE OF THE AMERICAS, 47TH FLOOR, NEW YORK NY 10105
Judy R Joice	officer: Sr. VP Operations & Corp QA	10260 BUBB ROAD, CUPERTINO CA 95014
21 April Fund Lp	10 percent owner	1345 AVENUE OF THE AMERICAS, 47TH FLOOR, New York NY 10105
Jon S Saxe	director	FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Michael Arenberg	officer: Chief Financial Officer	10260 BUBB ROAD, CUPERTINO CA 95014
James E Brown	director, officer: President & CEO	10240 BUBB RD, CUPERTINO CA 95014
First Eagle Investment Management, Llc	10 percent owner	1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105